PROFUSA INC
PFSANASDAQTrading Snapshot
- Day Range
- $2.26 – $2.30
- 52-Week Range
- $1.58 – $3,000.00
- Volume
- $3.18B
- Avg Volume
- $2.44B
- Shares Outstanding
- 1.1M
- Next Earnings
- Nov 27, 2026
Fundamentals Snapshot
- Annual Revenue
- $189,608
- Last Q Revenue
- $49,373
- P/E Ratio
- -0.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-745.02
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +4667.4%
Why Investors Own PFSA
- ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
PROFUSA INC
PFSA
StockOtter · stockotter.spaceAbout PROFUSA INC
Profusa, Inc. is a pioneering health technology firm that engineers advanced, bio-integrated sensors. These innovative devices, exemplified by their Lumee™ Oxygen Platform, are designed for uninterrupted observation of internal physiological markers. By leveraging artificial intelligence, Profusa translates this constant stream of data into actionable health insights, primarily to empower individuals and clinicians in the management of persistent health challenges like diabetes and critical limb ischemia.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head to Head Review: OraSure Technologies (NASDAQ:OSUR) and Profusa (NASDAQ:PFSA)
Profusa (NASDAQ: PFSA - Get Free Report) and OraSure Technologies (NASDAQ: OSUR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on th
Micro Cap Profusa Navigates European Regulatory Hurdles to Advance Oxygen Monitoring Tech
Micro cap Profusa, Inc. (NASDAQ:PFSA) stock is surging on Thursday after the company received a positive decision from GMED regarding the certification of its quality management system to ISO 13485.
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision
Profusa, Inc. Receives Nasdaq Compliance Determination
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Letter”) from The Nasd
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LL
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock